โครเอเชีย - โครเอเชีย - HALMED (Agencija za lijekove i medicinske proizvode)

teva b.v., swensweg 5, haarlem, nizozemska - acitretin - kapsula, tvrda - 10 mg - urbroj: jedna tvrda kapsula sadrži 10 mg acitretina

โครเอเชีย - โครเอเชีย - HALMED (Agencija za lijekove i medicinske proizvode)

teva b.v., swensweg 5, haarlem, nizozemska - acitretin - kapsula, tvrda - 25 mg - urbroj: jedna tvrda kapsula sadrži 25 mg acitretina

โครเอเชีย - โครเอเชีย - HALMED (Agencija za lijekove i medicinske proizvode)

ren medica d.o.o., polača - uređaj za hemodijalizu bolesnika

สหภาพยุโรป - โครเอเชีย - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - afatinib - karcinom, ne-malih stanica pluća - antineoplastična sredstva - giotrif u monoterapiji namijenjen za liječenje ofepidermal ako uređaj primatelja faktor rasta (РЭФР) тки-naivnih odraslih pacijenata sa lokalno-uobičajena ili metastatskih немелкоклеточным raka pluća (НМРЛ) koja aktivira mutacije РЭФР (- s);lokalno-uobičajena ili metastatskih НМРЛ pločastih stanica гистологии napreduje ili nakon kemoterapije платиносодержащей.

สหภาพยุโรป - โครเอเชีย - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - Толваптан - policistični bubreg, autosomno dominantan - diuretici, - jinarc je naznačeno da se usporiti napredovanje cista razvoj i bubrežnom insuficijencijom autosomno dominantnom policističnom bolešću bubrega (adpkd) u odraslih osoba s ckd pozornica 1 do 3 na početak liječenja s dokazima o brzo napreduje bolest.

บอสเนียและเฮอร์เซโกวีนา - โครเอเชีย - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

pro.med. bh d.o.o. - пропафенона - film tableta - 150 mg/1 tableta - 1 tableta sadrži 150 mg propafenona

สหภาพยุโรป - โครเอเชีย - EMA (European Medicines Agency)

novartis europharm limited - lapatinib - neoplazme dojki - inhibitori протеинкиназы - tyverb indiciran za liječenje bolesnika s rakom dojke, tumori kojima je prisutna gena her2 i (Еrbв2):u kombinaciji s капецитабином za liječenje održao ili метастатического bolesti s napredovanje nakon prethodnog tretmana, koji bi trebao biti uključen антрациклины i таксаны i terapija трастузумабом kada метастатическом instalacija;u kombinaciji s трастузумабом u bolesnika s hormon-receptor negativni metastatskih bolesti koje прогрессировало prilikom трастузумаб terapija ili terapija u kombinaciji s kemoterapijom, u kombinaciji s inhibitor aromataze za žene u postmenopauzi s hormon-receptor pozitivnim metastatskih bolesti, trenutno nisu namijenjeni za kemoterapije. pacijenti u регистрационном istraživanju ranije nije postupalo s трастузумабом ili inhibitor aromataze . nema podataka o učinkovitosti ove kombinacije relativno трастузумаб u kombinaciji s inhibitor aromataze u ovoj populaciji pacijenata .

สหภาพยุโรป - โครเอเชีย - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - neoplazme dojki - antineoplastična sredstva - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

สหภาพยุโรป - โครเอเชีย - EMA (European Medicines Agency)

akebia europe limited - željeznog citrata - hyperphosphatemia; renal dialysis - lijekovi za liječenje hiperkalemije i hiperfosfatemije - fexeric je indiciran za kontrolu hiperfosfatemije u odraslih bolesnika s kroničnom bolesti bubrega (ckd).

โครเอเชีย - โครเอเชีย - HALMED (Agencija za lijekove i medicinske proizvode)

abbvie d.o.o., strojarska cesta 20, zagreb, hrvatska - parikalcitol - kapsula, meka - 1 mikrogram - urbroj: jedna meka kapsula sadrži 1 mikrogram parikalcitola